Abstract
AbstractThe CLKs (Cdc2-like kinases) belong to the dual-specificity protein kinase family and play crucial roles in regulating transcript splicing via the phosphorylation of SR proteins (SRSF1–12), catalyzing spliceosome molecular machinery, and modulating the activities or expression of non-splicing proteins. The dysregulation of these processes is linked with various diseases, including neurodegenerative diseases, Duchenne muscular dystrophy, inflammatory diseases, viral replication, and cancer. Thus, CLKs have been considered as potential therapeutic targets, and significant efforts have been exerted to discover potent CLKs inhibitors. In particular, clinical trials aiming to assess the activities of the small molecules Lorecivivint on knee Osteoarthritis patients, and Cirtuvivint and Silmitasertib in different advanced tumors have been investigated for therapeutic usage. In this review, we comprehensively documented the structure and biological functions of CLKs in various human diseases and summarized the significance of related inhibitors in therapeutics. Our discussion highlights the most recent CLKs research, paving the way for the clinical treatment of various human diseases.
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference173 articles.
1. Myers, M. P., Murphy, M. B. & Landreth, G. The dual-specificity CLK kinase induces neuronal differentiation of PC12 cells. Mol. Cell Biol. 14, 6954–6961 (1994).
2. Petsalaki, E. & Zachos, G. Clks 1, 2 and 4 prevent chromatin breakage by regulating the Aurora B-dependent abscission checkpoint. Nat. Commun. 7, 11451 (2016).
3. Bullock, A. N. et al. Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. Structure 17, 352–362 (2009).
4. Jain, P. et al. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer’s disease. Curr. Drug Targets 15, 539–550 (2014).
5. Jiang, K. et al. Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid. Endocrinology 150, 2087–2097 (2009).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献